

Moon-Kyu Lee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6572397/moon-kyu-lee-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

692
citations

16
h-index

25
g-index

40
ext. papers

840
ext. citations

5
avg, IF

3.77
L-index

#	Paper	IF	Citations
37	East Asian diet-mimicking diet plan based on the Mediterranean diet and the Dietary Approaches to Stop Hypertension diet in adults with type 2 diabetes: A randomized controlled trial. <i>Journal of Diabetes Investigation</i> , 2021 , 12, 357-364	3.9	3
36	Glucolipotoxicity and GLP-1 secretion. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	2
35	Delayed heart rate recovery after exercise predicts development of metabolic syndrome: A retrospective cohort study. <i>Journal of Diabetes Investigation</i> , 2021 ,	3.9	2
34	Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. <i>Diabetes and Metabolism Journal</i> , 2021 , 45, 933-947	5	0
33	Blood glucose control: Where are we?. <i>Journal of Diabetes Investigation</i> , 2021 , 12, 1762-1764	3.9	
32	Diabetes and COVID-19: IDF perspective in the Western Pacific region. <i>Diabetes Research and Clinical Practice</i> , 2020 , 166, 108278	7.4	3
31	Association of Body Mass Index with the Risk of Incident Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality: A Community-Based Prospective Study. <i>Endocrinology and Metabolism</i> , 2020 , 35, 416-424	3.5	3
30	Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Diabetes and Metabolism Journal</i> , 2020 , 44, 78-90	5	3
29	Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort. <i>Diabetes and Metabolism Journal</i> , 2020 , 44, 458-469	5	5
28	Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study). <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1527-1536	6.7	8
27	Effect of Blood Pressure on Cardiovascular Diseases at 10-Year Follow-Up. <i>American Journal of Cardiology</i> , 2019 , 123, 1654-1659	3	1
26	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. <i>Journal of Diabetes Investigation</i> , 2019 , 10, 418-428	3.9	13
25	Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study. <i>Journal of Korean Medical Science</i> , 2019 , 34, e117	4.7	3
24	Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial. <i>Diabetes and Metabolism Journal</i> , 2019 , 43, 422-431	5	4
23	Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 631-639	6.7	5
22	Baseline level and change in serum albumin concentration and the risk of incident type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 61-66	3.2	4
21	Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2408-2415	6.7	24

20	Relationship between serum bilirubin levels and cardiovascular disease. <i>PLoS ONE</i> , 2018 , 13, e0193041	3.7	24
19	Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status. <i>Diabetes and Metabolism Journal</i> , 2018 , 42, 415-424	5	64
18	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. <i>International Journal of Clinical Practice</i> , 2017 , 71, e12987	2.9	4
17	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. <i>Diabetes and Metabolism Journal</i> , 2017 , 41, 135-145	5	14
16	Delayed heart rate recovery after exercise as a risk factor of incident type 2 diabetes mellitus after adjusting for glycometabolic parameters in men. <i>International Journal of Cardiology</i> , 2016 , 221, 17-22	3.2	11
15	Serum uric acid: A strong and independent predictor of metabolic syndrome after adjusting for body composition. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 432-40	12.7	57
14	Change in serum albumin concentration is inversely and independently associated with risk of incident metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2016 , 65, 1629-1635	12.7	18
13	Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. <i>Diabetes Care</i> , 2015 , 38, 1245-52	14.6	42
12	A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 295-306	7.5	29
11	Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. <i>European Journal of Endocrinology</i> , 2015 , 173, 313-23	6.5	26
10	Cardiovascular disease incidence, mortality and case fatality related to diabetes and metabolic syndrome: A community-based prospective study (Ansung-Ansan cohort 2001-12). <i>Journal of Diabetes</i> , 2015 , 7, 791-9	3.8	20
9	Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. <i>Diabetes Research and Clinical Practice</i> , 2014 , 104, 266-72	7.4	42
8	Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. <i>Journal of Endocrinology</i> , 2014 , 220, 117-28	4.7	41
7	Glucagon/insulin ratio in preoperative screening before pancreatic surgery: correlation with hemoglobin A1C in subjects with and without pancreatic cancer. <i>Endocrine</i> , 2014 , 47, 493-9	4	6
6	Metabolic syndrome and cardiovascular diseases in Korea. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014 , 21 Suppl 1, S31-5	4	21
5	Sex factors in the metabolic syndrome as a predictor of cardiovascular disease. <i>Endocrinology and Metabolism</i> , 2014 , 29, 522-9	3.5	14
4	Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. <i>International Journal of Cardiology</i> , 2013 , 168, 2678-83	3.3	51
3	PPAR- δ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β cells. <i>PLoS ONE</i> , 2013 , 8, e50128	3.7	74

2	Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 367, 623-9	3.4	33
1	The Effect of Continuous Ambulatory Peritoneal Dialysis on Change in Serum Leptin. <i>Peritoneal Dialysis International</i> , 1999 , 19, 172-175	2.8	17